English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Chronic hepatitis B still represents a major challenge for clinicians and the public health service even years after the development of an effi cient vaccine and potent antiviral agents. The major actual problems in treating chronic hepatitis B (HBV) patients are represented by the lack of reliable biomarkers which can predict the response to specifi c types of therapy. With the availability of different treatment options for chronic HBV patients at our disposal [Pegylated Interferon (pegIFN), Nucleosidic Analogues (NUCs), combined therapies] the results of treatment remain modest. A better selection of patients for each treatment regimen requires an early predictive factor for treatment effi ciency especially with NUC therapies witch tend to have a very long treatment period (up to fi ve decades) for reaching HBs clearance. The main objective of our study is to identify the most important predictive factors for early NUC treatment response. We observed that baseline quantitative HBs antigen (qHBsAg) levels, rapid qHBsAg decrease rate in the fi rst year of treatment and high ALT levels are important predictors for HBs antigen loss while the decrease rate of HBV-DNA and the treatment regimen are not reliable predictive factors.

Key Factors Influencing qHBsAg Dynamics in Chronic Hepatitis B Patients During Treatment with Direct Acting Antivirals